70 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
RDY Dr. Reddy's Laboratories Ltd $35.7 $5.93B N/A
Article Searches
New Strong Sell Stocks for November 11th http://www.zacks.com/stock/news/614102/new-strong-sell-stocks-for-november-11th?cid=CS-ZC-FT-tale_of_the_tape|new_zacks_#5_rank_stocks-614102 Nov 11, 2019 - Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Dr. Reddy's Laboratories Ltd (RDY) CEO Erez Israeli on Q2 2020 Results - Earnings Call Transcript https://seekingalpha.com/article/4301629-dr-reddys-laboratories-ltd-rdy-ceo-erez-israeli-q2-2020-results-earnings-call-transcript?source=feed_tag_india Nov 01, 2019 - Dr. Reddy's Laboratories Ltd (NYSE:RDY) Q2 2020 Earnings Conference Call November 01, 2019, 09:00 ET Company Participants Amit Agarwal - Director, Finance, FP&A and IR Saumen Chakraborty - Preside
Mylan (MYL) to Pay $30M to Settle SEC Charges for EpiPen http://www.zacks.com/stock/news/543304/mylan-myl-to-pay-%2430m-to-settle-sec-charges-for-epipen?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-543304 Sep 30, 2019 - Mylan (MYL) sinks after the SEC charges it for misclassification of EpiPen.
The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power http://www.zacks.com/stock/news/532018/the-zacks-analyst-blog-highlights-dr-reddys-wns-and-azure-power?cid=CS-ZC-FT-press_releases-532018 Sep 23, 2019 - The Zacks Analyst Blog Highlights: Dr. Reddy's, WNS and Azure Power
Is it Apt to Foray Into the Indian Stock Market?: An Analysis http://www.zacks.com/stock/news/527926/is-it-apt-to-foray-into-the-indian-stock-market-an-analysis?cid=CS-ZC-FT-analyst_blog|investment_ideas-527926 Sep 20, 2019 - The government of India unveils an array of concessions to spur the economy. This in turn will slash most corporate taxes to 22% while new manufacturers will pay even a lower corporate tax rate of 15%.
J&J's Prostate Cancer Drug Gets FDA Nod for Expanded Use http://www.zacks.com/stock/news/526368/jjs-prostate-cancer-drug-gets-fda-nod-for-expanded-use?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-526368 Sep 19, 2019 - J&J's (JNJ) sNDA seeking approval of Erleada for metastatic castration-sensitive prostate cancer is based on data from TITAN study.
Zynerba Releases Data on Epilepsy Candidate, Stock Down http://www.zacks.com/stock/news/526215/zynerba-releases-data-on-epilepsy-candidate-stock-down?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-526215 Sep 19, 2019 - Zynerba (ZYNE) announces positive top-line results from the BELIEVE 1 study evaluating the efficacy and safety of Zygel in a heterogeneous group of rare and ultra-rare epilepsies.
Top Ranked Momentum Stocks to Buy for September 17th http://www.zacks.com/commentary/522889/top-ranked-momentum-stocks-to-buy-for-september-17th?cid=CS-ZC-FT-zacks_#1_rank_additions-522889 Sep 17, 2019 - Top Ranked Momentum Stocks to Buy for September 17th
Dr. Reddy's Reports Positive Top-Line Data on Psoriasis Drug http://www.zacks.com/stock/news/427399/dr-reddys-reports-positive-top-line-data-on-psoriasis-drug?cid=CS-ZC-FT-427399 Jun 10, 2019 - Dr. Reddy's (RDY) reports positive top-line results from the phase IIb study on PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis.
BioMarin's Vimizim Wins Nod in China for Rare Genetic Malady http://www.zacks.com/stock/news/425808/biomarins-vimizim-wins-nod-in-china-for-rare-genetic-malady?cid=CS-ZC-FT-425808 Jun 06, 2019 - BioMarin's (BMRN) Vimizim gains an NMPA nod in China for addressing patients suffering Morquio A syndrome, an ultra-rare genetic condition.

Pages: 1234567

Page 1>